Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
18 juil. 2024 08h30 HE
|
Nexalin Technology, Inc.
‘Breaking Barriers’ Coalition Formed to Address Opioid Use Disorder in the USA Nexalin CEO Mark White Participates in Inaugural Meeting HOUSTON, TX, July 18, 2024 (GLOBE NEWSWIRE) --...
Nexalin Technology Announces Closing of $5.2 Million Public Offering
01 juil. 2024 14h45 HE
|
Nexalin Technology, Inc.
HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of...
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
27 juin 2024 21h15 HE
|
Nexalin Technology, Inc.
HOUSTON, TX, June 27, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the pricing of a public offering of 3,000,000 shares of...
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
26 juin 2024 09h00 HE
|
Nexalin Technology, Inc.
Study demonstrates strong statistical separation between patients receiving Nexalin’s DIFS® technology in combination with escitalopram (Lexapro) vs sham group receiving escitalopram alone Two-thirds...
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
20 juin 2024 08h30 HE
|
Nexalin Technology, Inc.
HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office...
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
13 juin 2024 15h00 HE
|
Nexalin Technology, Inc.
HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA)...
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
04 juin 2024 08h30 HE
|
Nexalin Technology, Inc.
HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo...
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
03 juin 2024 08h30 HE
|
Nexalin Technology, Inc.
HOUSTON, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announces that the U.S. Food and Drug Administration (FDA) has provided...
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
22 mai 2024 08h30 HE
|
Nexalin Technology, Inc.
HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected...
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
09 mai 2024 08h30 HE
|
Nexalin Technology, Inc.
HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET. ...